Citigroup’s Ascendis Pharma A/S ASND Stock Holding History

Citigroup’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.74M	Sell	12,000 -63,900	-84%	-$14.3M	﹤0.01%	2449
2025 Q4	$16.2M	Buy	+75,900	New	+$15.7M	0.01%	1224
2024 Q3	–	Sell	-12,500	Closed	-$1.7M	–	5674
2024 Q2	$1.7M	Sell	12,500 -12,300	-50%	-$1.67M	﹤0.01%	2476
2024 Q1	$3.75M	Sell	24,800 -3,400	-12%	-$485K	﹤0.01%	1930
2023 Q4	$3.55M	Buy	28,200 +3,200	+13%	+$319K	﹤0.01%	1824
2023 Q3	$2.34M	Hold	25,000	–	–	﹤0.01%	1889
2023 Q2	$2.23M	Hold	25,000	–	–	﹤0.01%	2100
2023 Q1	$2.68M	Buy	25,000 +800	+3%	+$91.5K	﹤0.01%	1828
2022 Q4	$2.96M	Buy	+24,200	New	+$2.81M	﹤0.01%	1781

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Citigroup's ASND Position: Q1 2026 in Review

Citigroup reduced its Ascendis Pharma A/S (ASND) stake by 3.7% in Q1 2026, selling an estimated $256K and leaving 29,701 shares worth $6.79M. The position accounts for ﹤0.01% of the portfolio, ranked #1722.

Citigroup first reported a position in ASND in Q1 2015 and has held it in 34 quarters since. 273 funds tracked by Wall St. Rank hold ASND as of Q1 2026.

Citigroup held 29,701 shares of Ascendis Pharma A/S worth $6.79M as of Q1 2026.
Citigroup sold 1,142 Ascendis Pharma A/S shares in Q1 2026, an estimated $256K.
Ascendis Pharma A/S made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #1722 holding.
Citigroup first reported a position in Ascendis Pharma A/S in Q1 2015 and has held it in 34 quarters since.
273 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.